Anika Therapeutics | ANIK - Gross Profit On Sales

Stock Price
14.40
Daily Change
0.04 0.28%
Monthly
39.81%
Yearly
-15.44%
Q1 Forecast
13.92

Anika Therapeutics reported $14.68M in Gross Profit on Sales for its fiscal quarter ending in March of 2025.





Gross Profit On Sales Change Date
Abbott USD 6.54B 625M Dec/2025
Agenus USD 23.93M 2.79M Mar/2025
Agios Pharmaceuticals USD 18.09M 6.89M Dec/2025
Anika Therapeutics USD 14.68M 9.46M Mar/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
Heron Therapeutics USD 23.35M 1.6M Sep/2024
Insmed USD 217.69M 106.25M Dec/2025
Integra LifeSciences USD 217.1M 10.11M Dec/2025
Intrexon USD -297K 167K Jun/2024
J&J USD 16.6B 118M Dec/2025
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
Ligand Pharmaceuticals USD 155.28M 82.42M Sep/2025
MacroGenics USD 61.25M 88.71M Sep/2025
Merit Medical Systems USD 195.35M 8.94M Dec/2025
Rigel Pharmaceuticals USD 28.49M 7.01M Jun/2024
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sanofi EUR 8.45B 1.31B Dec/2025
Smith & Nephew USD 2.09B 117M Dec/2025
Stryker USD 4.49B 633M Dec/2025
Surmodics USD -11.54M 3.99M Sep/2024
Veracyte USD 101.97M 10.69M Dec/2025
Xencor USD 21M 22.61M Sep/2025
Zimmer Biomet Holdings USD 1.27B 8.1M Dec/2025